泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301230 泓博医药

已收盘 04-24 15:00:00

{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":43.36,"timestamp":1777014237000,"preClose":42.78,"halted":0,"volume":9669032,"delay":0,"changeRate":0.0136,"floatShares":126000000,"shares":140000000,"eps":0.2622,"marketStatus":"已收盘","change":0.58,"latestTime":"04-24 15:00:00","open":42.57,"high":44.74,"low":42.1,"amount":422000000,"amplitude":0.0617,"askPrice":43.36,"askSize":33,"bidPrice":43.35,"bidSize":12,"shortable":0,"etf":0,"ttmEps":0.2622,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":42.78,"symbolType":"stock","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":47.06,"lowLimit":38.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":139586605,"isCdr":false,"pbRate":5.82,"roa":"--","peRate":165.369947,"roe":"3.3%","epsLYR":0.12,"committee":-0.531987,"marketValue":6052000000,"turnoverRate":0.077,"status":0,"floatMarketCap":5447000000},"requestUrl":"/m/hq/s/301230","defaultTab":"news","newsList":[{"id":"2629201540","title":"4月22日泓博医药涨9.80%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629201540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629201540?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:34","pubTimestamp":1776846897,"startTime":"0","endTime":"0","summary":"证券之星消息，4月22日泓博医药涨9.80%，收盘报43.82元，换手率11.11%，成交量13.96万手，成交额5.76亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.1122，较上一交易日下跌1.16%，近一年上涨10.67%。该公募基金现任基金经理为龙宇飞。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628798976","title":"股市必读：泓博医药(301230)股东户数2.39万户，较上期减少4.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628798976","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628798976?lang=zh_cn&edition=full","pubTime":"2026-04-20 01:37","pubTimestamp":1776620227,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，泓博医药报收于40.06元，下跌2.36%，换手率5.56%，成交量6.99万手，成交额2.8亿元。股本股东变化股东户数变动近日泓博医药披露，截至2026年4月10日公司股东户数为2.39万户，较3月31日减少1091.0户，减幅为4.36%。户均持股数量由上期的5578.0股增加至5832.0股，户均持股市值为23.25万元。根据中登公司下发的股东名册，截至2026年4月10日（交易日），公司的股东户数为23,935户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000000807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628796282","title":"泓博医药：截至2026年4月10日股东户数为23,935户","url":"https://stock-news.laohu8.com/highlight/detail?id=2628796282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628796282?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:24","pubTimestamp":1776414264,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)04月17日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截止到2026年4月15日收盘公司股东人数是多少？谢谢！泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年4月10日（交易日），公司的股东户数为23,935户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700030461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657429","title":"泓博医药：公司与药石科技未开展相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657429","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624657429?lang=zh_cn&edition=full","pubTime":"2026-04-03 19:38","pubTimestamp":1775216280,"startTime":"0","endTime":"0","summary":"证券日报网讯4月3日，泓博医药在互动平台回答投资者提问时表示，截至目前，公司与药石科技未开展相关合作。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-03/doc-inhtfrev3672977.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-03/doc-inhtfrev3672977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","300725","301230","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624656576","title":"泓博医药：截至2026年3月31日股东户数为25,026户","url":"https://stock-news.laohu8.com/highlight/detail?id=2624656576","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624656576?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:54","pubTimestamp":1775206443,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)04月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截止到2026年3月31日公司股东人数是多少？谢谢！泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年3月31日(交易日)，公司的股东户数为25,026户。感谢关注！为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260403/32124756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624765514","title":"4月3日泓博医药跌7.58%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624765514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624765514?lang=zh_cn&edition=full","pubTime":"2026-04-03 16:17","pubTimestamp":1775204275,"startTime":"0","endTime":"0","summary":"证券之星消息，4月3日泓博医药跌7.58%，收盘报40.99元，换手率11.85%，成交量14.89万手，成交额6.25亿元。重仓泓博医药的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.1331，较上一交易日下跌0.99%，近一年上涨2.89%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300031342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624330595","title":"4月1日泓博医药涨7.83%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624330595","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624330595?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:19","pubTimestamp":1775031553,"startTime":"0","endTime":"0","summary":"证券之星消息，4月1日泓博医药涨7.83%，收盘报43.79元，换手率18.03%，成交量22.65万手，成交额9.51亿元。重仓泓博医药的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.0955，较上一交易日下跌1.32%，近一年上涨0.87%。该公募基金现任基金经理为龙宇飞。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100029177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623239700","title":"3月30日泓博医药涨6.86%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623239700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623239700?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:29","pubTimestamp":1774859381,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日泓博医药涨6.86%，收盘报39.43元，换手率14.65%，成交量18.41万手，成交额7.35亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.102，较上一交易日上涨2.52%，近一年上涨0.38%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622361849","title":"3月27日泓博医药涨5.52%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622361849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622361849?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:18","pubTimestamp":1774599508,"startTime":"0","endTime":"0","summary":"证券之星消息，3月27日泓博医药涨5.52%，收盘报36.9元，换手率5.08%，成交量6.38万手，成交额2.31亿元。重仓泓博医药的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A目前规模为4.74亿元，最新净值1.0749，较上一交易日下跌1.65%，近一年下跌2.1%。该公募基金现任基金经理为龙宇飞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700033494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621059046","title":"泓博医药：截至2026年3月20日股东户数为19,571户","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059046?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:15","pubTimestamp":1774336524,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)03月24日在投资者关系平台上答复投资者关心的问题。投资者提问：公司最新股东人数泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年3月20日（交易日），公司的股东户数为19,571户。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400019846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620316172","title":"彩讯股份：公司暂未与泓博医药合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620316172","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620316172?lang=zh_cn&edition=full","pubTime":"2026-03-18 17:48","pubTimestamp":1773827300,"startTime":"0","endTime":"0","summary":"证券之星消息，彩讯股份(300634)03月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，注意到公司在布局AI制药相关方面，也注意到公司在和泓博医药有AI制药AI大模型相关的合作，泓博医药可以说是国内AI制药第一股，现在市值这么低潜力这么巨大，公司为什么不直接控股或者收购呢彩讯股份回复：尊敬的投资者，您好！公司暂未与泓博医药合作，暂无上述安排，请以公司公告为准。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800032428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0231","300634","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427884","title":"泓博医药：围绕相关技术方向构建了以DiOrion平台为核心的药物研发体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620427884?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:52","pubTimestamp":1773751961,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月16日在投资者关系平台上答复投资者关心的问题。公司围绕相关技术方向构建了以DiOrion平台为核心的药物研发体系，覆盖靶点发现、分子设计与优化、成药性预测等关键环节。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620942738","title":"凯普生物：公司与您提及的泓博医药暂无相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942738","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620942738?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:52","pubTimestamp":1773751934,"startTime":"0","endTime":"0","summary":"证券之星消息，凯普生物(300639)03月16日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，注意到公司在布局AI制药相关方面，也注意到公司在和泓博医药有AI制药AI大模型相关的合作，泓博医药可以说是国内AI制药第一股，现在市值这么低潜力这么巨大，公司为什么不直接控股或者收购呢凯普生物回复：您好，感谢您的关注。公司与您提及的泓博医药暂无相关合作，关于公司的对外投资情况请留意公司的相关公告及定期报告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0239","BK0046","BK0132","BK0216","300639","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619327964","title":"泓博医药：公司目前的DiOrion平台主要由公司自主研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2619327964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619327964?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:07","pubTimestamp":1773644835,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月15日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，想了解公司与深势科技目前合作的具体进展： 1.双方在AI药物研发、分子模拟、Hermite平台、Uni-FEP计算等方面的合作推进到哪一阶段？公司与深势科技此前有过合作，相关技术也在公司早期项目中进行了应用。公司目前的DiOrion平台主要由公司自主研发，双方并未开展合作研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600014261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619065100","title":"股市必读：泓博医药(301230)股东户数2.06万户，较上期减少2.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619065100","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619065100?lang=zh_cn&edition=full","pubTime":"2026-03-16 02:43","pubTimestamp":1773600190,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，泓博医药报收于39.59元，下跌1.07%，换手率2.43%，成交量3.05万手，成交额1.21亿元。当日关注点来自交易信息汇总：3月13日主力资金净流出454.96万元，散户资金净流入498.27万元。股本股东变化股东户数变动近日泓博医药披露，截至2026年3月10日公司股东户数为2.06万户，较2月27日减少632.0户，减幅为2.98%。户均持股数量由上期的6585.0股增加至6787.0股，户均持股市值为28.04万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619197739","title":"泓博医药：目前不存在应披露而未披露的战略投资、股权合作等方面的重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197739","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619197739?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:51","pubTimestamp":1773406289,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月12日在投资者关系平台上答复投资者关心的问题。目前公司不存在应披露而未披露的战略投资、股权合作等方面的重大事项。未来如涉及相关重大事项，公司将严格依据法律法规和监管要求，及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300038405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619340198","title":"康龙化成：公司与泓博医药没有合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2619340198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619340198?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:24","pubTimestamp":1773393853,"startTime":"0","endTime":"0","summary":"证券之星消息，康龙化成(300759)03月13日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，注意到公司在布局AI制药相关方面，也注意到公司在和泓博医药有AI制药AI大模型相关的合作，泓博医药可以说是国内AI制药第一股，现在市值这么低潜力这么巨大，公司为什么不直接控股或者收购呢康龙化成回复：尊敬的投资者您好，公司与泓博医药没有合作，对该公司情况不了解，亦无相关收购计划，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300029729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300759","301230","BK1576","BK0216","BK1141","03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618922495","title":"股市必读：泓博医药（301230）3月11日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618922495?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:27","pubTimestamp":1773250030,"startTime":"0","endTime":"0","summary":"截至2026年3月11日收盘，泓博医药报收于40.73元，下跌1.43%，换手率2.79%，成交量3.51万手，成交额1.44亿元。公司密切关注前沿技术的发展和应用，并在药物发现领域围绕智能体方向开展了探索工作。目前上述工作尚处于内部探索阶段，暂未形成可对外披露的重大进展。当日关注点来自交易信息汇总：3月11日主力资金净流出640.64万元，散户资金净流入656.06万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200000913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618288947","title":"泓博医药：目前上述工作尚处于内部探索阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2618288947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618288947?lang=zh_cn&edition=full","pubTime":"2026-03-11 20:52","pubTimestamp":1773233572,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药03月11日在投资者关系平台上答复投资者关心的问题。公司密切关注前沿技术的发展和应用，并在药物发现领域围绕智能体方向开展了探索工作。目前上述工作尚处于内部探索阶段，暂未形成可对外披露的重大进展。公司将根据业务需求及整体规划稳步推进相关研究，请您以公司公告或定期报告发布的内容为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031100037468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618623303","title":"泓博医药：公司的客户及订单情况属于未公开信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623303","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618623303?lang=zh_cn&edition=full","pubTime":"2026-03-09 19:03","pubTimestamp":1773054180,"startTime":"0","endTime":"0","summary":"登录新浪财经APP 搜索【信披】查看更多考评等级\n　　证券日报网讯 3月9日，泓博医药在互动平台回答投资者提问时表示，公司的客户及订单情况属于未公开信息，敬请以公司在指定信息披露平台发布的公告和定期报告为准。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-09/doc-inhqkxfq0651688.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-09/doc-inhqkxfq0651688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777203255234,"stockEarnings":[{"period":"1week","weight":0.0824},{"period":"1month","weight":0.229},{"period":"3month","weight":-0.1221},{"period":"6month","weight":0.308},{"period":"1year","weight":0.6073},{"period":"ytd","weight":0.4547}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"23935人(较上一季度减少4.36%)","perCapita":"5248股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"13958万元","survey":"　　上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是替格瑞洛API及关键中间体、帕拉米韦中间体、左卡尼汀、奥拉西坦、本维莫德。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}